AR069691A1 - Derivados ciclopropilamina - Google Patents
Derivados ciclopropilaminaInfo
- Publication number
- AR069691A1 AR069691A1 ARP080105430A ARP080105430A AR069691A1 AR 069691 A1 AR069691 A1 AR 069691A1 AR P080105430 A ARP080105430 A AR P080105430A AR P080105430 A ARP080105430 A AR P080105430A AR 069691 A1 AR069691 A1 AR 069691A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- independently selected
- hydroxyalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
Estos compuestos son utiles para tratar condiciones o trastornos que se pueden prevenir o mejorar mediante los ligandos del receptor de histamina-3. También se divulgan composiciones farmacéuticas que comprenden los ligandos del receptor de histamina-3 y métodos de tratamiento terapéutico: trastornos de la atencion, déficit de memoria y aprendizaje, esquizofrenia, Alzheimer, epilepsia, discapacidad cognitiva leve. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) o una sal aceptable para uso farmacéutico, éster, amida o prodroga del mismo, en donde: uno de R1 y R2 es un grupo de la formula -L2-R6a-L3-R6b; el otro de R1 y R2 se selecciona entre el grupo que consiste de hidrogeno, alquilo, alcoxi, halogeno, ciano, y tioalcoxi; R3, R3a, y R3b cada uno se selecciona en forma independiente entre el grupo que consiste de hidrogeno, alquilo, trifluoroalquilo, trifluoroalcoxi, alcoxi, halogeno, ciano, y tioalcoxi; R4 y R5 cada uno se selecciona en forma independiente entre el grupo que consiste de alquilo, fluoroalquilo, hidroxialquilo, alcoxialquilo, y cicloalquilo, o R4 y R5 tomados junto con el átomo de nitrogeno al cual cada uno se encuentra unido forman un anillo no aromático de la formula (2) o (3); R7, R8, R9, y R10 en cada oportunidad cada uno se selecciona en forma independiente entre el grupo que consiste de hidrogeno, hidroxialquilo, fluoroalquilo, cicloalquilo, y alquilo; R11, R12, R13, y R14 cada uno se selecciona en forma independiente entre el grupo que consiste de hidrogeno, hidroxialquilo, alquilo, y fluoroalquilo; R6a se selecciona entre el grupo que consiste de un anillo heteroarilo de 5 o 6 miembros, cianofenilo, un anillo heteroarilo bicíclico de 8 a 12 miembros, y un anillo heterocíclico de 4 a 12 miembros; R6b se selecciona entre el grupo que consiste de hidrogeno, un anillo heteroarilo de 5 o 6 miembros, un anillo arilo, un anillo heteroarilo bicíclico de 8 a 12 miembros, y un anillo heterocíclico de 4 a 12 miembros; Q es O o S; L es -[C(R16)(R17)]k; L2 se selecciona entre el grupo que consiste de una union, alquileno, -O-, -C(=O)-, -S-, -NH-, -N(R16)C(=O)-, -C(=O)N(R16), y -N(alquilo)-; L3 se selecciona entre el grupo que consiste de una union, alquileno, -O-, -C(=O)-, -S-, -N(R16)C(=O)-, -C(=O)N(R16), y -N(R15)-; R15 se selecciona entre el grupo que consiste de hidrogeno, alquilo, acilo, alcoxicarbonilo, amido, y formilo; R16 y R17 en cada oportunidad se seleccionan en forma independiente entre el grupo que consiste de hidrogeno y alquilo; Rx y Ry en cada oportunidad se seleccionan en forma independiente entre el grupo que consiste de hidrogeno, hidroxi, hidroxialquilo, alquilo, alcoxi, alquilamino, fluoro, y dialquilamino; k es 1, 2 o 3; y m es un entero de 1 a 5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/956,816 US9108948B2 (en) | 2006-06-23 | 2007-12-14 | Cyclopropyl amine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069691A1 true AR069691A1 (es) | 2010-02-10 |
Family
ID=40589783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105430A AR069691A1 (es) | 2007-12-14 | 2008-12-12 | Derivados ciclopropilamina |
Country Status (23)
Country | Link |
---|---|
US (1) | US9108948B2 (es) |
EP (1) | EP2231631A1 (es) |
JP (1) | JP5649975B2 (es) |
KR (1) | KR20100095011A (es) |
CN (2) | CN103483234A (es) |
AR (1) | AR069691A1 (es) |
AU (1) | AU2008338748B2 (es) |
BR (1) | BRPI0821258A2 (es) |
CA (1) | CA2709081C (es) |
CO (1) | CO6290643A2 (es) |
CR (1) | CR11500A (es) |
DO (1) | DOP2010000181A (es) |
EC (1) | ECSP10010253A (es) |
GT (1) | GT201000170A (es) |
IL (1) | IL206254A0 (es) |
MX (1) | MX2010006535A (es) |
NZ (2) | NZ601644A (es) |
PA (1) | PA8807301A1 (es) |
PE (1) | PE20091428A1 (es) |
RU (1) | RU2010129078A (es) |
UA (1) | UA97036C2 (es) |
WO (1) | WO2009079225A1 (es) |
ZA (1) | ZA201004655B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007150010A2 (en) * | 2006-06-23 | 2007-12-27 | Abbott Laboratories | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
RS53144B (en) * | 2007-08-22 | 2014-06-30 | Astrazeneca Ab. | DERIVATES CYCLOPROPIL AMIDA |
US20090221648A1 (en) * | 2007-12-21 | 2009-09-03 | Abbott Laboratories | Compositions for treatment of cognitive disorders |
US8383657B2 (en) * | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
WO2011011277A1 (en) * | 2009-07-23 | 2011-01-27 | State Of Oregon Acting By & Through The State Board Of Higher Education On Behalf Of Oregon State University | Inhibitor(s) of transporters or uptake of monoaminergic neurotransmitters |
SG183231A1 (en) * | 2010-02-18 | 2012-09-27 | Astrazeneca Ab | Solid forms comprising a cyclopropyl amide derivative |
JP2013520414A (ja) | 2010-02-18 | 2013-06-06 | アストラゼネカ・アクチエボラーグ | シクロプロピルベンズアミド誘導体の新規な結晶形態 |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物 |
CN105102448B (zh) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
WO2015171489A1 (en) * | 2014-05-05 | 2015-11-12 | Apicore Us Llc | Methods of making netupitant and intermediates thereof |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL128365C (es) | 1963-11-05 | |||
FR2508033A1 (fr) * | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses |
EP0188887B1 (en) | 1985-01-17 | 1991-05-02 | Imperial Chemical Industries Plc | Tertiary amine compounds |
GB8501169D0 (en) * | 1985-01-17 | 1985-02-20 | Ici Plc | Heterocyclic compounds |
GB8615313D0 (en) | 1986-06-23 | 1986-07-30 | Ici Plc | Chemical process |
GB8621790D0 (en) | 1986-09-10 | 1986-10-15 | Ici Plc | Tertiary amine compounds |
GB2210364A (en) | 1987-09-29 | 1989-06-07 | Ici Plc | Cyclopropane ring-containing tertiary amine derivatives |
US5086054A (en) * | 1990-07-31 | 1992-02-04 | Sri International | Novel arylcycloalkanepolyalkylamines |
GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9401436D0 (en) | 1994-01-26 | 1994-03-23 | Wellcome Found | Therapeutic heterocyclic compounds |
FR2716192B1 (fr) | 1994-02-17 | 1996-04-12 | Rhone Poulenc Agrochimie | Dérivés de 2-imidazoline-5-ones fongicides. |
ATE294778T1 (de) * | 1995-01-23 | 2005-05-15 | Daiichi Suntory Pharma Co Ltd | Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen |
FR2751645B1 (fr) * | 1996-07-29 | 1998-12-24 | Sanofi Sa | Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales |
DE19821002A1 (de) * | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP2000047358A (ja) | 1998-07-28 | 2000-02-18 | Fuji Photo Film Co Ltd | 感光材料処理装置 |
EP0982300A3 (en) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
WO2000042023A1 (en) | 1999-01-18 | 2000-07-20 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP2002542245A (ja) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 置換イミダゾール、それらの製造および使用 |
AU3957600A (en) | 1999-04-26 | 2000-11-10 | Boehringer Ingelheim International Gmbh | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
MXPA03000174A (es) * | 2000-07-06 | 2003-09-22 | Neurogen Corp | Ligandos de receptor de hormona concentradora de melanina. |
US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
US6515013B2 (en) * | 2000-07-13 | 2003-02-04 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
JP2004506012A (ja) | 2000-08-17 | 2004-02-26 | グリアテツク・インコーポレイテツド | H3剤としての新規脂環式イミダゾール |
AU2002219920A1 (en) | 2000-11-28 | 2002-06-11 | Sunesis Pharmaceuticals, Inc. | Salicylate analogs as interleukin-4 antagonists |
JP2002236340A (ja) | 2001-02-09 | 2002-08-23 | Konica Corp | ハロゲン化銀写真感光材料の自動現像機による処理方法 |
EP1370546A2 (en) | 2001-03-16 | 2003-12-17 | Abbott Laboratories | Novel amines as histamine-3 receptor ligands and their therapeutic applications |
US6969730B2 (en) * | 2001-03-16 | 2005-11-29 | Abbott Laboratories | Amines as histamine-3 receptor ligands and their therapeutic applications |
US7056906B2 (en) * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
US6575511B2 (en) * | 2001-10-22 | 2003-06-10 | Winston R. Hultstrand | Apparatus for removing snow from motor vehicles |
DE10153345A1 (de) | 2001-10-29 | 2003-05-08 | Gruenenthal Gmbh | Substituierte 1H-Chinoxalin-2-on-Verbindungen und substituierte 4-Aryl- und 4-Heteroarylcyclohexan-Verbindungen |
DE10153347A1 (de) | 2001-10-29 | 2003-05-08 | Gruenenthal Gmbh | Substituierte 1H-Chinolin-2-on-Verbindungen |
EP1321169A1 (en) | 2001-12-18 | 2003-06-25 | Biofrontera Pharmaceuticals AG | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament |
PE20030701A1 (es) * | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
MXPA04007612A (es) | 2002-02-05 | 2004-11-10 | Novo Nordisk As | Aril- y heteroarilpiperazinas novedosas. |
TW200307667A (en) | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
US7312214B2 (en) | 2002-05-10 | 2007-12-25 | Bristol-Myers Squibb Company | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors |
AU2003229535A1 (en) | 2002-06-06 | 2003-12-22 | Novo Nordisk A/S | Substituted hexahydropyrrolo(1,2-a)pyrazines, octahydropyrido(1,2-a)pyrazines and decahydropyrazino(1,2-a)azepines |
JP2004131497A (ja) | 2002-09-18 | 2004-04-30 | Satoshi Shuto | シスシクロプロパン誘導体 |
DE60321207D1 (en) | 2002-09-19 | 2008-07-03 | Lilly Co Eli | Diaryläther als opioid-rezeptor antagonisten |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
KR101067732B1 (ko) | 2002-10-23 | 2011-09-28 | 얀센 파마슈티카 엔.브이. | 피페라지닐 및 디아자파닐 벤즈아미드 및 벤즈티오아미드 |
WO2004037813A1 (en) | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
US7153889B2 (en) * | 2002-11-12 | 2006-12-26 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
CA2765093A1 (en) | 2002-11-12 | 2004-05-27 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
JPWO2004046110A1 (ja) | 2002-11-15 | 2006-03-16 | アステラス製薬株式会社 | メラニン凝集ホルモン受容体拮抗剤 |
DK1572215T3 (da) * | 2002-12-20 | 2010-01-11 | Glaxo Group Ltd | Benzo[D]azepin-derivater til behandling af neurologiske lidelser |
JP4458333B2 (ja) * | 2003-02-13 | 2010-04-28 | キヤノン株式会社 | 露光装置、およびデバイスの製造方法 |
CA2523431A1 (en) | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
US8338120B2 (en) * | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
DK2206496T3 (da) * | 2003-05-05 | 2014-12-15 | Probiodrug Ag | Screening af inhibitorer af pyroglutaminsyredannelse i amyloid beta-peptid |
DK1620082T3 (da) | 2003-05-05 | 2010-08-16 | Probiodrug Ag | Medicinsk anvendelse af inhibitorer af glutaminyl- og glutamatcyclaser til behandling af Alzheimers sygdom og Downs syndrom |
US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
WO2004099199A1 (en) | 2003-05-06 | 2004-11-18 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
US7094790B2 (en) * | 2003-05-07 | 2006-08-22 | Abbott Laboratories | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
FR2856596B1 (fr) | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
WO2005009471A1 (en) | 2003-07-28 | 2005-02-03 | Osaka Industrial Promotion Organization | Composition for lowering blood-sugar level |
WO2005009976A1 (en) | 2003-07-29 | 2005-02-03 | Novo Nordisk A/S | Pyridazinyl- piperazines and their use as histamine h3 receptor ligands |
GB0319211D0 (en) | 2003-08-15 | 2003-09-17 | Koninkl Philips Electronics Nv | Antenna arrangement and a module and a radio communications apparatus having such an arrangement |
US7199149B2 (en) | 2003-10-01 | 2007-04-03 | Bristol Myers Squibb Company | Monocyclic and bicyclic lactams as factor Xa inhibitors |
JP5707014B2 (ja) * | 2003-10-15 | 2015-04-22 | プロビオドルグ エージー | グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用 |
JP4617837B2 (ja) | 2003-11-21 | 2011-01-26 | チッソ株式会社 | フッ化アルキレンを有する重合性を有する液晶性化合物およびその重合体 |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
EP1718309A2 (en) | 2004-01-30 | 2006-11-08 | Japan Tobacco, Inc. | Anorectic compounds |
BRPI0507374A (pt) * | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
NZ549046A (en) * | 2004-02-13 | 2010-06-25 | Banyu Pharma Co Ltd | Fused-ring 4-oxopyrimidine derivative |
GB0405628D0 (en) | 2004-03-12 | 2004-04-21 | Glaxo Group Ltd | Novel compounds |
JP2005281223A (ja) | 2004-03-30 | 2005-10-13 | Chisso Corp | 1,2−シクロヘキシレン環を有する光学活性化合物、液晶組成物、液晶表示素子、成形体 |
US7345034B2 (en) * | 2004-04-07 | 2008-03-18 | Abbott Laboratories | Azacyclosteroid histamine-3 receptor ligands |
US20050245529A1 (en) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
DE102004019492A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
PT1747210E (pt) | 2004-05-07 | 2010-08-31 | Warner Lambert Co | Derivados de fenol e de tiofenol 3- ou 4-monossubstituídos úteis enquanto ligandos de h3 |
US7205316B2 (en) * | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
US7098222B2 (en) * | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
TW200611701A (en) | 2004-06-18 | 2006-04-16 | Glaxo Group Ltd | Novel compounds |
JP4857267B2 (ja) | 2004-06-30 | 2012-01-18 | アサーシス, インク. | 認識障害、睡眠障害、肥満及びその他のcns障害を治療するためのヒスタミン3受容体インヒビターとなる非イミダゾール第三級アミン |
GB0418267D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
US20060074103A1 (en) * | 2004-10-06 | 2006-04-06 | Corte James R | Cyclic beta-amino acid derivatives as factor Xa inhibitors |
EP1802307B1 (en) | 2004-10-15 | 2008-02-27 | Glaxo Group Limited | Pyrrolidine derivatives as histamine receptors ligands |
KR20070091007A (ko) | 2004-12-07 | 2007-09-06 | 글락소 그룹 리미티드 | 인데닐 유도체 및 신경계 장애의 치료를 위한 이들의 용도 |
WO2006072596A1 (en) | 2005-01-07 | 2006-07-13 | Glaxo Group Limited | 6- (2 , 3 , 4 , 5-TETRAHYDRO-lH-BENZO [D] AZEPIN-7-YLOXY) -NICOTAMIDE DERIVATIVES AS RADIOLABELLED LIGANDS |
JP4211867B2 (ja) * | 2005-02-14 | 2009-01-21 | 萬有製薬株式会社 | 4(3h)−キナゾリノン誘導体の結晶 |
EP1851201A1 (en) | 2005-02-24 | 2007-11-07 | Glaxo Group Limited | 1-{4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine as histamine h3 antagonist |
ATE420091T1 (de) | 2005-03-14 | 2009-01-15 | Glaxo Group Ltd | Kondensierte thiazolderivate mit affinität für den histamin-h3-rezeptor |
EP1707204A1 (en) | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands |
EP1707203A1 (en) | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
WO2006124687A1 (en) | 2005-05-12 | 2006-11-23 | University Of Medicine And Dentistry Of New Jersey | Opioid receptor subtype-selective agents |
JP2008540618A (ja) | 2005-05-18 | 2008-11-20 | ブルスター,ジークフリート | ソマトスタチン受容体サブタイプ1及び/又は4に選択的なペプチド模倣薬 |
JP4981794B2 (ja) * | 2005-06-03 | 2012-07-25 | アボット・ラボラトリーズ | シクロブチルアミン誘導体 |
WO2006132424A1 (ja) | 2005-06-07 | 2006-12-14 | Banyu Pharmaceutical Co., Ltd. | 4(3h)-キナゾリノン誘導体の製造方法 |
CN103110635A (zh) | 2005-07-04 | 2013-05-22 | 海波因特制药有限责任公司 | 组胺h3受体拮抗剂 |
JP4240146B2 (ja) | 2005-07-05 | 2009-03-18 | 萬有製薬株式会社 | 4(3h)−キナゾリノン誘導体の製造方法 |
GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
US20090203750A1 (en) | 2005-08-24 | 2009-08-13 | Alan Kozikowski | 5-HT2C Receptor Agonists as Anorectic Agents |
DE602006017712D1 (de) * | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | Phenylpyridonderivat |
PT1948607E (pt) * | 2005-09-16 | 2010-06-02 | Janssen Pharmaceutica Nv | Ciclopropilaminas como moduladores do receptor h3 de histamina |
WO2007035703A1 (en) * | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
US7576110B2 (en) * | 2005-09-22 | 2009-08-18 | Abbott Laboratories | Benzothiazole cyclobutyl amine derivatives |
WO2007048595A1 (en) | 2005-10-27 | 2007-05-03 | Ucb Pharma, S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
CA2634152A1 (en) * | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | Trpa1 inhibitors for treating pain |
BRPI0707719A2 (pt) | 2006-02-10 | 2011-05-10 | Summit Corp Plc | uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo |
MX2008012406A (es) | 2006-03-31 | 2008-10-07 | Novartis Ag | Compuestos nuevos. |
SI2079732T1 (sl) | 2006-05-29 | 2012-03-30 | High Point Pharmaceuticals Llc | benzodioksol il ciklopropilpiperazin il piridazin njegove soli in solvati in njegova uporaba kot antagonist histaminskega receptorja H |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
WO2007150010A2 (en) * | 2006-06-23 | 2007-12-27 | Abbott Laboratories | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
EP2502918B1 (en) * | 2006-07-25 | 2015-03-25 | Cephalon, Inc. | Pyridazinone Derivatives |
WO2008064317A1 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Lipophilic opioid receptor active compounds |
WO2008064318A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Peripheral opioid receptor active compounds |
WO2008064310A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Mixed opioid receptor active compounds |
AU2007325350B2 (en) | 2006-11-29 | 2012-09-20 | Abbvie Inc. | Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme |
RU2430099C2 (ru) * | 2007-01-22 | 2011-09-27 | Пфайзер Продактс Инк. | Тозилатная соль терапевтического соединения и ее фармацевтические композиции |
CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
CL2008000596A1 (es) | 2007-03-01 | 2008-09-05 | Glaxo Group Ltd | Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas. |
MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
EP2167096A4 (en) * | 2007-06-13 | 2010-07-14 | Cypress Bioscience Inc | IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM |
CA2694264A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
CN101796032A (zh) * | 2007-06-28 | 2010-08-04 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
US20090036425A1 (en) * | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
PE20090510A1 (es) * | 2007-08-03 | 2009-05-22 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
RS53144B (en) | 2007-08-22 | 2014-06-30 | Astrazeneca Ab. | DERIVATES CYCLOPROPIL AMIDA |
TW200918527A (en) | 2007-09-06 | 2009-05-01 | Glaxo Group Ltd | Piperazine derivative having affinity for the histamine H3 receptor |
WO2009039431A2 (en) | 2007-09-21 | 2009-03-26 | Neurogen Corporation | Substituted aryl-fused spirocyclic amines |
US8153813B2 (en) | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
KR20100099738A (ko) | 2007-12-20 | 2010-09-13 | 아스트라제네카 아베 | Dgat1 억제제로서의 카르바모일 화합물 190 |
US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
MX2010007587A (es) * | 2008-01-24 | 2010-08-04 | Ucb Pharma Sa | Compuestos que comprenden un grupo ciclobutoxi. |
WO2009100120A2 (en) | 2008-02-04 | 2009-08-13 | Neurogen Corporation | Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines |
CN101990537A (zh) | 2008-02-07 | 2011-03-23 | 雅培制药有限公司 | 作为阳性别构调节剂的酰胺衍生物和其使用方法 |
WO2009115874A2 (en) | 2008-03-17 | 2009-09-24 | Matrix Laboratories Ltd. | Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation |
WO2009124553A2 (en) | 2008-04-09 | 2009-10-15 | Neurokey A/S | Use of hypothermia inducing drugs |
US20110098300A1 (en) | 2008-06-06 | 2011-04-28 | Ucb Pharma, S.A. | Compounds Comprising A Cyclobutoxy Group |
CA2727242A1 (en) | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of faah |
US8268846B2 (en) * | 2008-07-11 | 2012-09-18 | Abbott Laboratories | Amino heterocyclic linked pyrimidine derivatives |
MX2011000460A (es) | 2008-07-18 | 2011-03-15 | Takeda Pharmaceutical | Derivados de benzazepina y su uso como antagonistas de histamina h3. |
US9643922B2 (en) * | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
AU2009284092B2 (en) | 2008-08-20 | 2016-05-19 | Vivoryon Therapeutics N.V. | Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE) |
US20110245267A1 (en) | 2008-12-19 | 2011-10-06 | Schering Plough Corporation | Piperidine and piperazine derivatives and methods of use thereof |
WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US20100227876A1 (en) * | 2009-03-06 | 2010-09-09 | Rechfensen Llp | Methods of Reducing Side Effects of Analgesics |
US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
TW201141485A (en) | 2010-01-08 | 2011-12-01 | Takeda Pharmaceutical | Compounds and their use |
WO2011083315A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Compounds and their use |
WO2011083316A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
US8853390B2 (en) * | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
-
2007
- 2007-12-14 US US11/956,816 patent/US9108948B2/en not_active Expired - Fee Related
-
2008
- 2008-05-12 UA UAA201008762A patent/UA97036C2/ru unknown
- 2008-12-05 CA CA2709081A patent/CA2709081C/en not_active Expired - Fee Related
- 2008-12-05 NZ NZ601644A patent/NZ601644A/xx not_active IP Right Cessation
- 2008-12-05 RU RU2010129078/04A patent/RU2010129078A/ru not_active Application Discontinuation
- 2008-12-05 WO PCT/US2008/085622 patent/WO2009079225A1/en active Application Filing
- 2008-12-05 CN CN201310400583.2A patent/CN103483234A/zh active Pending
- 2008-12-05 MX MX2010006535A patent/MX2010006535A/es active IP Right Grant
- 2008-12-05 KR KR1020107015538A patent/KR20100095011A/ko not_active Application Discontinuation
- 2008-12-05 NZ NZ617334A patent/NZ617334A/en not_active IP Right Cessation
- 2008-12-05 JP JP2010538064A patent/JP5649975B2/ja not_active Expired - Fee Related
- 2008-12-05 AU AU2008338748A patent/AU2008338748B2/en not_active Ceased
- 2008-12-05 BR BRPI0821258-9A patent/BRPI0821258A2/pt not_active IP Right Cessation
- 2008-12-05 CN CN2008801268829A patent/CN101952267A/zh active Pending
- 2008-12-05 EP EP08861197A patent/EP2231631A1/en not_active Withdrawn
- 2008-12-11 PE PE2008002048A patent/PE20091428A1/es not_active Application Discontinuation
- 2008-12-11 PA PA20088807301A patent/PA8807301A1/es unknown
- 2008-12-12 AR ARP080105430A patent/AR069691A1/es unknown
-
2010
- 2010-06-08 IL IL206254A patent/IL206254A0/en unknown
- 2010-06-11 CO CO10070735A patent/CO6290643A2/es not_active Application Discontinuation
- 2010-06-11 GT GT201000170A patent/GT201000170A/es unknown
- 2010-06-14 CR CR11500A patent/CR11500A/es not_active Application Discontinuation
- 2010-06-14 DO DO2010000181A patent/DOP2010000181A/es unknown
- 2010-06-14 EC EC2010010253A patent/ECSP10010253A/es unknown
- 2010-07-01 ZA ZA2010/04655A patent/ZA201004655B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201004655B (en) | 2011-03-30 |
NZ617334A (en) | 2015-10-30 |
CN103483234A (zh) | 2014-01-01 |
CA2709081A1 (en) | 2009-06-25 |
CA2709081C (en) | 2016-03-22 |
AU2008338748B2 (en) | 2013-05-16 |
RU2010129078A (ru) | 2012-01-20 |
CR11500A (es) | 2010-10-11 |
KR20100095011A (ko) | 2010-08-27 |
MX2010006535A (es) | 2010-08-31 |
CO6290643A2 (es) | 2011-06-20 |
US9108948B2 (en) | 2015-08-18 |
PE20091428A1 (es) | 2009-10-24 |
JP2011506456A (ja) | 2011-03-03 |
DOP2010000181A (es) | 2010-06-30 |
GT201000170A (es) | 2012-04-03 |
NZ601644A (en) | 2013-11-29 |
CN101952267A (zh) | 2011-01-19 |
JP5649975B2 (ja) | 2015-01-07 |
BRPI0821258A2 (pt) | 2015-06-16 |
IL206254A0 (en) | 2010-12-30 |
WO2009079225A1 (en) | 2009-06-25 |
AU2008338748A1 (en) | 2009-06-25 |
EP2231631A1 (en) | 2010-09-29 |
ECSP10010253A (es) | 2010-07-30 |
PA8807301A1 (es) | 2009-07-23 |
US20080242653A1 (en) | 2008-10-02 |
UA97036C2 (en) | 2011-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069691A1 (es) | Derivados ciclopropilamina | |
AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR051091A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
AR051094A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR043180A1 (es) | Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
AR051294A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR051090A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
AR073574A1 (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
AR051092A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa | |
AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
AR049696A1 (es) | Derivados de indol | |
AR040048A1 (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |